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Contexte 
Facteurs pronostiques dans le plasmocytome isolé osseux : 
une étude du Rare Cancer Network 
Le plasmocytome isolé osseux est une tumeur maligne rare des cellules plasmocytaires. Les 
données issues de la littérature ne permettent pas de se détem1iner sur la dose 
radiothérapeutique optimale. Dans cette perspective nous avons conduit une vaste étude 
rétrospective dans le but d'évaluer l'évolution, les facteurs pronostiques aunsi que la dose 
radiothérapeutique optimale chez les patients présentant un plasmocytome isolé. 
Méthodes 
Nous avons réunis les données de 206 patients présentant un plasmocytome isolé osseux sans 
évidence de myélome multiple. Chaque cas a été documenté histopathologiquement. La 
majorité des patients (n=l 69) ont été traités par radiothérapie seule, 32 par une combinaison 
radiothérapie-chimiothérapie, et 5 par chirurgie. La durée de suivi médiane fut de 54 mois (7-
245) 
Résultats 
A 5 ans, la survie globale est de 70%, la survie sans maladie de 46% et le contrôle local de 
88%. La durée médiane de développement vers une myélome multiple est de 21 mois (2-13 5) 
avec une probabilité à 5 ans de 51%. Les analyses multivariées indiquent l'âge (<60 ans) et la 
taille de la tumeur (<Sem) comme facteur favorables pour survie. L'âge (<60ans) se dégage 
comme facteur favorable pour la survie sans maladie. La localisation de la tumeur (vertébrale 
vs autre) indique la probabilité de contrôle local. L'âge plus avancé (>60 ans) est le seul 
prédicteur de myélome multiple. Aucune relation dose-réponse n'est mise en évidence pour 
les doses supérieures à 30 Gy, même pour les tumeurs les plus étendues. 
Conclusions 
Les patients les plus jeunes, principalement ceux présentant une localisation vertébrale, 
présentent la meilleure évolution sous traitement radiothérapeutique modéré. La progression 
vers le myélome multiple reste le problème thérapeutique principal. Les futures investigations 
devraient se focaliser sur les chimiothérapies adjuvantes ainsi que sur les nouveaux agents 
thérapeutiques. 
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Abstract 
Background: Solitary plasmacytoma (SP) of the bone is a rare plasma-cell neoplasm. There are 
no conclusive data in the literature on the optimal radiation therapy (RT) dose in SP. Therefore, in 
this large retrospective study, we wanted to assess the outcome, prognostic factors, and the 
optimal RT dose in patients with SP. 
Methods: Data from 206 patients with bone SP without evidence of multiple myeloma (MM) were 
collected. Histopathological diagnosis was obtained for ail patients. The majority (n = 169) of the 
patients received RT alone; 32 chemotherapy and RT, and 5 surgery. Median follow-up was 54 
months (7-245). 
Results: Five-year overall survival, disease-free survival (DFS), and local control was 70%, 46%, and 
88%; respectively. Median time to MM development was 21 months (2-135) with a 5-year 
probability of 51 %. ln multivariate analyses, favorable factors were younger age and tumor size < 5 
cm for survival; younger age for DFS; anatomie localization (vertebra vs. other) for local control. 
Older age was the only predictor for MM. There was no dose-response relationship for doses 30 
Gy or higher, even for larger tumors. 
Conclusion: Younger patients, especially those with vertebral localization have the best outcome 
when treated with moderate-dose RT. Progression to MM remains the main problem. Further 
investigation should focus on adjuvant chemotherapy and/or novel therapeutic agents. 
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Table 1: Characteristics of 206 patients with bone plasmacytoma 
Number of patients Percentage 
Staging Work-up 
Bone-marrow assessment 
Standard X-rays 
Computer tomography 
Serum immunoglobulins 
lmmunosubtraction 
MRI 
Bone scintigraphy 
Site o( lesion 
Yertebrae 
Pelvis 
Ribs 
Upper extremities 
Maxillary bone 
Skull 
Lower extremities 
Sternum 
Surgical intervention 
Biopsy 
Partial resection 
Complete resection 
Treatment 
RT alone 
CT+RT 
Surgery alone ( +CT in one) 
206 
167 
135 
120 
131 
76 
60 
102 
26 
18 
16 
13 
11 
10 
10 
137 
66 
169 
32 
5 
100 
82 
67 
58 
64 
37 
29 
50 
12 
9 
8 
6 
5 
5 
67 
32 
1 
82 
16 
2 
MRI: magnetic resonance imaging, RT: radiation therapy, CT: chemotherapy. 
Background 
Solitary plasmacytoma (SP) is a rare plasma-cell neo-
plasm [ 1 J. There are two separate entities, dependent on 
the location of the lesion originating in either bone or 
eA.'1.ramedullary soft tissue [2]. It is defined as a prolifera-
tion of monoclonal plasma cells without evidence of sig-
nificant bone-marrow plasma-cell infiltration [1]. Borre 
SP is characterized by a unique lesion involving any part 
of the squeleton, most commonly in the spine. 
Recommendations for the choice of treatment moda!ities 
in this radiosensitive disease [3 J are based mainly on data 
from retrospective studies often considering relatively 
small numbers of patients, with a limited ability to make 
any robust conclusions [4,5], and only one prospective 
study including 53 patients [ 6]. 
Definitive radiation therapy (RT) is the treatment of 
choice for solitary plasmacytoma giving adequate local 
control. However, vdth respect to long-term outcome, it is 
known that bone plasmacytoma progresses more fre-
quently to multiple myeloma (MM) than soft-tissue plas-
macytoma [7-9]. 
There are no conclusive data in the literature on the opti-
mal RT dose in SP. Many authors reported a wide range of 
doses varying from 30-66 Gy [10-12]. Most centers use 50 
Gy or more to treat SP, vl'ithout any strong evidence 
whether doses higher than 30 Gy are needed. 
We report herein the results of a retrospective multicenter 
study of a large cohort of patients vdth bone SP from 
European and North American centers, assessing treat-
ment approaches, radiation dose-response effects and dif-
ferent prognostic factors for survival, myeloma 
progression, and patterns of!ocal failure. 
Methods 
Between 197'7 and 2001, 206 adult patients consecutively 
treated for a bone SP vvithout evidence of MM were col-
lected in a retrospective multicenter study of the Rare Can-
cer Network (RCN). The review board of the RCN granted 
ethical approval for this study, and individual centers 
obtained individual ethical approval according to their 
local regulations for retrospective studies. The study 
included all patients vi'ith a new diagnosis ofbone SP and 
considered candidates for curative RT. According to the 
ne>-11 International Myeloma \l\Torking Group (IMWG) cri-
teria [13], a patient can be considered to have a bone SP if 
there is no M-protein in serum and/or urine (a small M-
component may sometimes be present); only a single area 
of bone destruction related to clonai plasma cells; no 
bone marrow infiltration; normal skeletal survey includ-
ing spine and pelvic MRI; and no end-organ damage other 
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Table 2: Distribution of local relapses according to biologically effective radiation dose* 
Ali patients (n = 206) Tumors? 5 cm (n = 59) 
R.adiation dose (Gy) Number of patients Local relapse (%) Number of patients Local relapse (%) 
No R.T*'' 5 4 (80%) 1 (100%) 
<30 25 2 (8%) 2 0 
? 30- <40 55 5 (9%) 17 3 (18%) 
? 40- <50 65 8 (12%) 15 3 (20%) 
? 50 56 8 (13%) 24 4 (17%) 
R.T: radiation therapy 
*biologically effective dose (BED) according to the linear-quadratic model.13 
BED = nd( 1 + [ d+u/J)]) where n = number of fractions, d = dose per fraction, and u/J) = 10 for plasmacytoma. 
**Ali patients treated with surgery alone (with chemotherapy in one). 
than solitary bone lesion. Our study, which was designed 
and conducted before the publication of the IM\VG guide-
lines, only the following criteria were used: a patient was 
considered to have a bone SP if there is a biopsy-proven 
solitary bone lesion; <10% plasma cells in the bone-mar-
row biopsy; no additional pathological lesions in the skel-
etal diagnostic work-up; no anemia; and normal blood 
chemistry. The median age was 60 years (range: 18-87), 
and the male-to-female ratio was 1.82. Pathological diag-
nosis was obtained in ail patients, by biopsy in 137, par-
tial resection in 66, and complete resection in 9 patients. 
Spinal column was the most frequent tumor site ( n = 
102 ). Initial diagnostic work-up was done according to 
standard recommendations current at the time of diagno-
sis. Magnetic-resonance imaging (MRI) was used only in 
76 patients (37%). The largest diameter of the lesion was 
recorded in 104 patients (50%), and its median value was 
5 cm (range: 1-18 cm). It was 5 =or more in 59 patients 
(29%), and less than 5 cm in 45 (22%). Serum immu-
noglobulin levels, a factor which indicates the possibility 
of occult disseminated disease, were reported in 120 
patients (median 6.5 g/l; range: 0-82); however, mye-
loma ( M) protein levels were not assessed follml'ing RT 
[11 ]. In this series, serum immunoglobulin level more 
than 20 g/1 was recorded only in 18 patients. Serum elec-
trophoresis and immunofixation were performed in 131 
patients. Beta-2 microglobulin data were recorded only 
for 60 patients. Human immunodeficiency-virus testing 
was done in only 5 patients, and ail were negative. Table 
1 summarizes the characteristics of ail patients. Median 
follow-up was 54 months (range: 7-245). 
Treatment 
Ail but 5 patients received RT. Surgical treatment was 
implemented in 69 (33%) patients (partial resection in 
66, and complete excision in 3). Chemotherapywas given 
in 32 ( 16%) patients. The planning RT volume included 
the radiologically visible gross tumor volume with a suffi-
cient margin. For vertebral SP, the planning RT volume 
included one vertebra above and below the involved ver-
tebra. No attempt was made to cover regional lymph 
nodes. Median dose was 40 Gy (range: 20-64); median 
number of fractions was 20 (range: 4-33) using a median 
dose of 2 Gy per fraction (range: 1.25-5). To facilitate the 
comparison of the different fractionation schedules used 
by different centers, we computed the 2-Gy per fraction 
biologically effective dose (BED) according to the linear-
quadratic mode!: BED = nd(l+ [d+a/0]); where a/0 = 10 
for plasmacytoma; n = number of fractions; and d = dose 
per fraction [14]. Median BED was 40.00 Gy (range: 
18.75-66.00). 
Six cycles (range: 1-12) of chemotherapy consisting of 
melphalan and prednisone (n = 23; 72%), vincristine, 
doxorubicin and dexamethasone (VAD) (n = 7; 22%), 
and other combinations ( n = 2; 6%) were administered in 
32 (16%) patients. 
Statistica/ methods 
Overall survival (OS), disease-free survival (DFS), local 
control, and time to MM progression were estimated 
using the product-limit method [15]. Time to any event 
was measured from the date ofhistological diagnosis. The 
events were death (ail causes) for OS, and death (ail 
causes) or relapse and/or progression to MM for DFS. For 
the local control rate, the event consisted of local failure, 
censoring patients without local relapse. For progression 
to MM, ail patients without MM progression were cen-
sored. Confidence intervals (CI) were calculated from 
standard errors. Differences between groups were assessed 
using the log rank test [16]. Multivariate analyses were 
done using the Cox stepvl'ise-regression analysis to deter-
mine the independent contribution of each prognostic 
factor [ 17]. 
Results 
Local control 
Median time to local relapse was 20 months (range: 2-
148), and was observed in 13% of the patients (n = 27). 
No regional lymph node relapse was observed. The 5- and 
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Table 3: Univariate analyses (logrank test) 
n 10-yr. %95 Cl p-value 10-yr. %95 Cl p-value 10-yr. %95 Cl p-value 10-yr. %95 Cl p-value 
OS(%) (%) DFS (%) (%) LC (%) (%) MM(%) (%) 
Ali 206 52 43-61 25 15-35 79 69-89 72 62-82 
patients 
Age (year) 
::; 60 103 63 50-76 <0.0001 29 16-42 0.02 79 64-94 0.46 67 53-81 0.007 
>60 03 34 19-49 22 9-35 79 67-91 76 62-90 
Gender 
Fern 73 52 36-68 0.98 38 23-53 0.79 88 79-97 0.60 58 43-73 0.77 
ale 
Male 133 49 37-61 23 13-33 75 62-88 74 63-85 
Site of plasmacytoma 
Vert 102 52 38-66 0.99 19 4-34 0.89 89 79-98 0.07 79 64-94 0.39 
ebra 
Othe 104 48 35-61 28 16-40 78 68-88 66 53-79 
Larges! tumor dimension (cm) 
<5 45 67 36-98 0.001 24 7-41 0.73 87 75-99 0.47 79 58-100 0.31 
2 5 59 57 42-72 34 19-49 78 65-91 58 42-74 
NA 102 33 19-47 16 0-33 73 50-96 80 64-96 
lgM subtype 
Ka pp 59 49 19-47 0.57 0 0.57 60 24-94 0.49 91 75-100 0.36 
a 
Lam 31 61 40-81 35 16-54 87 69-100 65 46-84 
bda 
100 
NA 116 49 37-61 22 20-44 84 75-93 64 52-76 
Type of treatment 
RT 169 51 40-62 0.49 27 16-38 0.92 78 66-90 0.27 71 60-82 0.93 
alon 
e 
CT 32 43 20-66 15 0-39 93 84- 77 54-100 
+RT 
100 
2 Gy/fr equiva/ent RT dose (Gy)' 
2 50 56 47 28-66 0.50 26 10-42 0.06 82 68-96 <0.0001 71 55-87 0.25 
2 40 65 55 34-76 25 6-44 67 40-94 78 59-97 
and 
<50 
2 30 55 46 28-64 32 16-48 90 81-99 63 47-79 
and 
<40 
<30 25 37 13-61 17 0-43 96 88-100 81 53-100 
No 5 0 0 0 33 0-86 
Rî' 
OS: overall survival; Cl: confidence interval; DFS: disease-free survival; LC: local control; MM: progression to multiple myeloma; NA: not available; 
CT: chemotherapy; RT: radiation therapy •biologically effective dose (BED) according to the linear-quadratic model.13 BED = nd(I + [d+a/0]) where 
n = number of fractions, d = dose per fraction, and a/0 = 10 for plasmacytoma. bnot significant when excluding patients not receiving radiation 
therapy. 'Ali patients treated with surgery alone (with chemotherapy in one). 
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Figure 1 
Actuarial local contrai rate according to biologically equiva-
lent dose at 2 Gy per fraction (no radiation therapy: solid/ 
double-dot line; <30 Gy: solid line; 30-39 Gy: dashed line; 
40-49 Gy: solid/single-dot line; = 50 Gy: dotted line) in 206 
patients with solitary bone plasmacytoma (p < 0.0001 but not 
significant when excluding non irradiated patients). 
10-year probability of local control was 88% (95% CI: 
83-93) and 79% (95% CI: 69-89), respectively. Ten-year 
local control according to the RT dose and to other candi-
date factors is shovm in Tables 2 and 3. \Vhen considering 
patients with tumor diameters of 5 cm or larger (n = 59), 
likewise there was no clear benefit from higher doses. 
However, patients with vertebral lesions seemed to have a 
better outcome in terms oflocal control (Tables 3 and 4). 
There were 4 (80%) local relapses out of 5 patients who 
were treated vdth surgery vvith or without chemotherapy 
compared to 21 (14%) out of 148 who received RT al one, 
and 2 ( 7%) out of 3 0 who received RT and chemotherapy. 
Surgery (RT vs. partial or complete resection and RT) did 
not influence the 10-year probability of local control 
(80% [95% CI: 71-89) vs. 74% [95% CI: 47-100], p = 
0.35). After adjusting RT dose to 2 Gy per fraction biolog-
ically equivalent dose, no dose-response relationship was 
observed for doses higher than 30 Gy (15 x 2 Gy; Fig. 1, 
Table 2). Among 201 irradiated patients, there were 2 
(7%) local failures out of 29 patients treated with = 30 Gy 
vs. 20 (12%) out of 168 treated with > 30 Gy. 
Progression to multiple myeloma 
Median time to development of MM was 21 months 
(range: 2-135). One hundred and forth (104) patients 
developed MM with a 5- and 10-year projected probabil-
ity of 51% (95% CI: 43-59) and 72% (95% CI: 62-82), 
respectively (Fig. 2). Among the 120 patients where base-
http://www.biomedcentral.com/1471-2407/6/118 
line immunoglobulin levels were recorded (median: 6.5 
g/l; range: 0-82), 10 of 18 patients whose levels were 
above 20 g/l developed MM progression compared to 53 
of 102 whose immunoglobulin levels were 20 g/l or less 
(chi-square: 0.079; p = 0.78). Moreover, in a logistic 
regression analysis assessing the influence of baseline 
serum immunoglobulin level on the development of MM, 
no significant correlation was found (R-square: 0.002; p = 
0.60). Ten-year probability of progression to MM accord-
ing to the type of SP and to other factors is shown in Table 
3. The only unfavorable factor for myeloma development 
was older age (> 60 years) in univariate analyses. The 10-
year probability of progression to MM was not influenced 
by anatomical location (79% forvertebra vs. 67% other; p 
= O. 73). MRI examination during staging work-up was not 
significantly associated with the 10-year probability of 
progression to MM (71% in both groups, p = 0.22). 
Surviva/ 
At the time of analysis, 135 patients were alive (50 \Vith 
disease), and 71 had <lied (54 died of disease including 2 
\Nith unknown causes, 16 related to intercurrent disease, 
and 1 from cardiopulmonary disease probably related to 
mediastinal RT). 
In ail patients, the 5- and 10-year probability of OS were 
70% (95% CI: 63-77) and 50% (95% Cl: 40-60), respec-
tively; and for 5- and 10-year DFS, 46% (95% CI: 38-54) 
and 25% (95% CI: 16-34), respectively. 
In univariate analyses, statistically significant best factors 
influencing the OS were younger age ( 60 years or 
younger), and tumor size ( < 5 cm). Ten-year probabilities 
of OS and DFS according to different prognostic factors 
are shown in Table 3. 
Multivariate analyses 
Multivariate analyses revealed that the best independent 
factors predicting the outcome were: younger age (RR = 
0.59; p < 0.00001) and tumors Jess than 5 cm (RR = 0.56; 
p = 0.0007) for OS; younger age (RR = 0.79; p = 0.02) for 
DFS; and vertebra localization (RR = 0.63; p = 0.04) for 
local control. Older age (RR =O. 78; p = 0.01) was the only 
independent predictor for MM development. 
Toxicity 
Early side effects according to CTC v2.0 depended on the 
irradiated anatomical regions [ 18]. Grade 1 toxicity was 
observed in 46 patients (22% ), grade 2 in 14 (7% ), and 
grade 3 in 4 (2%). 
According to the RTOG/EORTC late effect scoring system 
[19], grade 1 toxicitywas observed in one patient (asymp-
tomatic bone necrosis ), no grade 2 toxicity, and grade 3 
toxicity in 2 (femoral head necrosis in one, and xerosto-
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Actuarial probability of progression to multiple myeloma in 
206 patients. 
mia in the other). Grade 4 pulmonary toxicrty was 
observed in one patient who <lied from cardiopulmonary 
disease probably related to mediastinal RT to:xicity. 
Discussion 
\l\Te recently reported our e:>.-perience on a series of 258 
patients including bone and e:>.'tramedullary SP [20]. In 
the present study, we wanted to specifically assess differ-
ent treatment approaches, radiation dose-response effects; 
and different prognostic factors in patients with bone 
plasmacytoma. Severa! factors are reported to influence 
the outcome of SP in the literature [2,8, 10, 12,20-24]. 
Despite good local contrai with RT, patients with bone SP 
progresses to MM more frequently than those vvith 
e:>.1:ramedullary SP [7, 10]. Many questions remain unan-
swered about prognostic factors influencing the outcome 
and radiation dose-response, probably due to the limited 
number of patients included in reported series [9, 12,24 ]. 
This may be related to the Jack of routine use of MRl to 
exclude occult lesions at initial diagnosis [25,26]. MR1 
was done in only 33% of our patients (Table 1). Staging 
using MR1 to exclude multiple lesions has contributed in 
recent years to more accurate diagnosis of SP, since only 
the patients Vi1ith truly solitary involvement are eligible for 
curative RT [25,26]. This may also help radiation oncolo-
gists to define target radiation volumes vvith higher preci-
sion [27]. Unfortunately, in this study, whether MR1 
examination was done or not did not result in an 
improved ability to predict progression to MM. However, 
it was not clear how often MR1 was done to define the 
local extent of disease, rather than for the detection of 
occult disease in other bony sites such as füe spine and 
pelvis. Nevertheless, in our patients who had an MR1 
http://www.biomedcentral.com/1471-2407/6/118 
examination, no occult asymptomatic MM lesions were 
detected. 
There is limited information in the literature regarding füe 
outcome of elderly patients with myeloma. Sorne series 
indicate that advanced age is clearly associated vvifü poor 
survival whereas others do not [28]. In our series older age 
(>60 years) was found to be a bad prognostic factor, either 
in univariate or multivariate analyses, in terms of OS, 
DFS, or progression to MM. This difference may be related 
to several reasons. In terms of survival, older patients who 
develop MM are possibly treated Vlrifü "Jess aggressive" 
treatrnents, or not included in prospective trials compared 
to younger patients [ 29]. However, it is difficult to find an 
explanation why our patients older than 60 years develop 
MM more frequently than the younger ones. 
Patients in this study seemed to develop MM in two peaks. 
A first peak during the first three years post treatment is 
probably due to undetected asymptomatic gross disease 
becoming more obvious; a second peak corresponding to 
a progression of pre\riously occult disease is observed after 
6-9 years (Fig. 2). A number of patients showed very late 
myeloma progression, even after 10 years. Of note, while 
vertebral disease has been reported to be a poor prognos-
tic factor compared to other bony localizations [7], in our 
series 50% of bone SP were located in the axial skeleton 
but no difference in terms of progression to MM was 
observed. However, in multivariate analysis, patients in 
our series with vertebral lesions had a better local control 
compared to other anatomical locations (Table 4). 
Progression to MM has been reported to be Jess frequent 
in younger patients, whose sunrival is also better 
[10,24,30,31 ]. Our study confirmed these reports, with 
progression to MM seen more frequently in older patients, 
and improved sunrival in younger patients (Fig. 3, Table 
3). However, local failure did not depend on age. 
Baseline immunoglobulin (M protein) levels are reported 
to be a predictive factor of occult disseminated disease, 
and almost ail experts agree that an M protein level of 20 
g/1 is crucial for the definition of SP [ 11, 13]. In our series; 
only 18 patients had an M protein level above 20 g/l, and 
no difference in terms of MM development was observed 
between patients with M protein levels above and below 
20 g/l. Furthermore, patients shm\ring persistent M pro-
tein levels for more than one year after RT are prone to 
progress to MM [30,32]. This factor could not be assessed 
in our series because we did not have adequate data on M 
protein level responses to treatment, and the correlation 
of progression to MM Vlrith M protein persistence. 
Tumor size is reported to be an important prognostic fac-
tor in terms of local control. Tsang et al [ 10 J reported a 
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Table 4: Multivariate analysis* (Cox model) in 201 irradiated patients 
Covariable os DFS 
RR p-va/ue RR 
Age (years) 0.59 <0.00001 0.79 
Localization 
(vertebra 
vs.other) 
Tumor size 0.56 0.0007 
(cm) (<5 vs. 
<:5) 
LC 
p-value RR p-va/ue 
0.02 
0.63 0.04 
MM 
RR 
0.78 
p-value 
0.01 
comment 
:S 60 years 
better 
vertebra 
better 
<5 cm 
better 
*including age, gender, localization, tumor size, lgM subtype, type of treatment, and biological/y equivalent radiation dose. 
OS: overall survival; DFS: disease-free survival; LC: local control; MM: progression to multiple myeloma 
better outcome for lesions less than 5 an, while other 
studies did not find tumor size to be a factor [32]. In our 
series, local control was higher for plasmacytomas meas-
uring Jess than 5 cm ( 91 % ) than for th ose 5 an or higher 
(73% ). It is important to note that size was not reported 
for 112 ( 43%) of the patients in our study (Table 3). 
In a large review of over 400 publications from 1905 to 
1997, AJexiou et al [33] reported evidence that surgery 
alone gave the best results for extramedullary bone plas-
macytoma when clear surgical margins were obtained. In 
the present series, 94 patients were treated by surgery vvith 
(n = 86) or without RT (n = 8). Nine (3%) had a complete 
resection with negative margins; of these, only one 
received adjuvant RT, and seven relapsed. This finding 
argues against proposing surgery alone, even in cases 
where complete resection is achieved. 
\Vhile radiation therapy is the treatment of choice for sol-
itary plasmacytoma, the evidence of its efficacy is solely 
based on small retrospective studies [ 34]. There is no clear 
RT dose-response relationship in the literature. The analy-
sis performed by Mendenhall et al [ 22 J suggested a mini-
mum dose of 40 Gy for optimal local control. Despite 
little evidence for a dose-response relationship above 30-
40 Gy [8,21,24], some authors propose doses between 40 
and 50 Gy for small lesions, and higher doses for larger 
tumors [23,26,34]. v\lhile Tsang et al [10] reported that 
there was no convincing dose-response relationship 
above 35 Gy for small lesions, they concluded that local 
control was related to the size of the lesion and suggested 
giving higher doses or combined modality treatment for 
bulky tumors. This has also been proposed by other 
groups [8]. 
Our data showed no correlation between local failure and 
radiation dose, even for large tumors (Fig. l, Table 2). Due 
to its retrospective nature, these results should be inter-
preted with caution. However, it included a large number 
of patients treated with a wide spectrum of RT doses, Vlrith 
the finding that 30 Gy in 2-Gy fractions, or a biologically 
equivalent regimen was sufficient. It appears from this 
study that administering a higher radiation dose may be 
unable to overcome the negative prognostic impact of a 
bulky tumor on local control, in comparison with smaller 
tumors (Table 2). In addition to size, it is possible that 
other poorly documented factors ( e.g. local invasiveness, 
proliferation rate, or morphologie grade) also impact on 
the risk of local relapse, and are confounding factors in a 
dose-response analysis. 
Chemotherapy, which is not considered as a standard of 
care in patients with SP, has been proposed by some 
investigators in the initial management ofbone plasmacy-
toma. Only one prospective study reported a benefit with 
combined chemotherapy and RT compared to RT alone 
[ 6]. The chemotherapy used consisted of melphalan-pred-
nisone given every six weeks for three years. AJthough a 
limited number of patients was included (n = 53), this 
study concluded that combined radiochemotherapy 
seems to increase remission and suf\rival duration. 
Targeting the mechanisms that control angiogenesis, 
which has an integral role in the pathophysiology of 
hematologic malignancies, could be an innovative thera-
peutic approach in the treatment of SP. Kumar et al [35] 
reported high-grade angiogenesis in 64% of tumors in 
their series of 25 bone SP patients, and found that angio-
genesis is highly correlated vvith progression to MM. 
Therefore, antiangiogenic compounds such as thalido-
mide, vascular-endothelial growth-factor, or proteasome 
inhibitors may be promising in this disease. 
Conclusion 
Overall, the results obtained in this study, to our knowl-
edge the largest series in the literature, are in accordance 
with other published series [4,5,8,9,12,21,23,24]. 
AJthough high rates of local control were obtained, sur-
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vival was disappointing because of progression to MM. 
Only a large prospective study conducted by collaborative 
groups could answer the unresolved questions in this rel-
atively rare disease. Follov,ring a complete staging work-
up, which may include very sensitive imaging tools such 
as positron-emission tomography [36,37], current evi-
dence supports the use of involved-field moderate-dose 
radiation therapy. Future investigation in phase II or III 
prospective trials should focus on the use of adjuvant 
chemotherapy and/or nove! therapeutic agents. 
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